- Home
- LXRX vs GAIN Comparison
LXRX vs GAIN Comparison
Compare LXRX & GAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXRX | GAIN |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | United States | United States |
| Employees | N/A | 70 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.9M | 558.3M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXRX | GAIN |
|---|---|---|
| Price | $1.68 | $16.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.15 | ★ $14.75 |
| AVG Volume (30 Days) | ★ 2.1M | 322.0K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 9.23% |
| EPS Growth | ★ 77.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,803,000.00 | N/A |
| Revenue This Year | N/A | $9.07 |
| Revenue Next Year | N/A | $7.32 |
| P/E Ratio | ★ N/A | $4.38 |
| Revenue Growth | ★ 60.24 | N/A |
| 52 Week Low | $0.51 | $13.14 |
| 52 Week High | $1.95 | $16.54 |
Technical Indicators
Market Signals| Indicator | LXRX | GAIN |
|---|---|---|
| Relative Strength Index (RSI) | 47.92 | 75.40 |
| Support Level | $1.47 | $13.67 |
| Resistance Level | $1.81 | N/A |
| Average True Range (ATR) | 0.10 | 0.32 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 31.25 | 85.30 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.